MedTrace Logo

Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice

NCT07663786 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 726

Last updated 2026-06-23

No results posted yet for this study

Summary

This study uses existing cancer registry and health record data to understand how nivolumab is used in routine care in the Netherlands for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach.

Conditions

  • Esophageal Adenocarcinoma
  • Gastro-esophageal Junction Adenocarcinoma
  • Gastric Adenocarcinoma

Interventions

DRUG

Nivolumab

As per product label

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-09
Primary Completion
2026-10-01
Completion
2027-02-01
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07663786 on ClinicalTrials.gov